Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT/EDIC study

Catherine L Martin, Barbara H Waberski, Rodica Pop-Busui, Patricia A Cleary, Sarah Catton, James W Albers, Eva L Feldman, William H Herman, DCCT/EDIC Research Group, Catherine L Martin, Barbara H Waberski, Rodica Pop-Busui, Patricia A Cleary, Sarah Catton, James W Albers, Eva L Feldman, William H Herman, DCCT/EDIC Research Group

Abstract

Objective: To describe the sensitivity, specificity, positive predictive value, and negative predictive value of vibration perception threshold (VPT) testing in subjects with type 1 diabetes relative to gold standard assessments of peripheral neuropathy.

Research design and methods: VPT was determined in 1,177 adults with type 1 diabetes 13-14 years after participating in a study of intensive (INT) versus conventional (CONV) diabetes treatment. Abnormal VPT was defined by values exceeding 2.5 SD above age-specific normal values. Signs and symptoms of peripheral neuropathy were assessed and electrodiagnostic studies were performed to establish definite clinical neuropathy, abnormal nerve conduction, and confirmed clinical neuropathy (the presence of both definite clinical neuropathy and abnormal nerve conduction).

Results: Thirty-seven percent of subjects had definite clinical neuropathy, 61% had abnormal nerve conduction, and 30% had confirmed clinical neuropathy. Abnormal VPT was more common among former CONV than among INT subjects (64 vs. 57%, P < 0.05) and was associated with older age. VPT was a sensitive measure of confirmed clinical neuropathy (87%) and of definite clinical neuropathy (80%) and a specific measure of abnormal nerve conduction (62%). Higher VPT cut points improved test sensitivity and lower cut points improved specificity. Areas under the receiver operating characteristic curves ranged from 0.71-0.83 and were higher for older than for younger subjects and highest for those with confirmed clinical neuropathy.

Conclusions: VPT was a sensitive measure of peripheral neuropathy. Future researchers may choose to select VPT cut points for defining abnormality based on the population studied and clinical outcome of interest.

Trial registration: ClinicalTrials.gov NCT00360893.

Figures

Figure 1
Figure 1
ROC curves for the accuracy of VPT testing at the great toe for predicting definite clinical neuropathy (A), abnormal nerve conduction (B), and confirmed clinical neuropathy (C) in all subjects. The ROC curves shown in D–F are for the accuracy of VPT in predicting definite clinical neuropathy (D), abnormal nerve conduction (E), and confirmed clinical neuropathy (F) among subjects aged 35–50 years, whereas G–I show ROC curves for the accuracy of VPT testing at the great toe for predicting definite clinical neuropathy (G), abnormal nerve conduction (H), and confirmed clinical neuropathy (I) for subjects aged 51–65 years. For each ROC curve, the VPT value corresponding to each decile of 1 − specificity is shown.
Figure 1
Figure 1
ROC curves for the accuracy of VPT testing at the great toe for predicting definite clinical neuropathy (A), abnormal nerve conduction (B), and confirmed clinical neuropathy (C) in all subjects. The ROC curves shown in D–F are for the accuracy of VPT in predicting definite clinical neuropathy (D), abnormal nerve conduction (E), and confirmed clinical neuropathy (F) among subjects aged 35–50 years, whereas G–I show ROC curves for the accuracy of VPT testing at the great toe for predicting definite clinical neuropathy (G), abnormal nerve conduction (H), and confirmed clinical neuropathy (I) for subjects aged 51–65 years. For each ROC curve, the VPT value corresponding to each decile of 1 − specificity is shown.
Figure 1
Figure 1
ROC curves for the accuracy of VPT testing at the great toe for predicting definite clinical neuropathy (A), abnormal nerve conduction (B), and confirmed clinical neuropathy (C) in all subjects. The ROC curves shown in D–F are for the accuracy of VPT in predicting definite clinical neuropathy (D), abnormal nerve conduction (E), and confirmed clinical neuropathy (F) among subjects aged 35–50 years, whereas G–I show ROC curves for the accuracy of VPT testing at the great toe for predicting definite clinical neuropathy (G), abnormal nerve conduction (H), and confirmed clinical neuropathy (I) for subjects aged 51–65 years. For each ROC curve, the VPT value corresponding to each decile of 1 − specificity is shown.

References

    1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–986
    1. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995;122:561–568
    1. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995;38:869–880
    1. Epidemiology of Diabetes Interventions and Complications (EDIC) Design, implementation, and preliminary results of a long-term follow-up for the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99–111
    1. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA: A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17:1281–1289
    1. Report and recommendations of the San Antonio Conference on Diabetic Neuropathy. Consensus statement Diabetes 1988;37:1000–1004
    1. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy Neurology 1992;42:1823–1839
    1. Martin C, Waberski B, Pop-Busui R, Albers J, Herman W, Cleary P: Same day intra-subject reproducibility of vibration perception threshold in type 1 diabetes. Diabetologia 2008;51:S506
    1. Arezzo J: Quantitative Sensory Testing of Vibration Threshold: Vibratron II. Clifton, NJ, Physitemp Instruments, 1993
    1. Cohen J: A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37–46
    1. Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561–577
    1. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D: American Diabetes Association Diabetic neuropathies: a statement from the American Diabetes Association. Diabetes Care 2005;28:956–962
    1. Malik RA, Tesfaye S, Newrick PG, Walker D, Rajbhandari SM, Siddique I, Sharma AK, Boulton AJ, King RH, Thomas PK, Ward JD: Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia 2005;48:578–585
    1. Young MJ, Breddy JL, Veves A, Boulton AJ: The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994;17:557–560
    1. Elliott J, Tesfaye S, Chaturvedi N, Gandhi RA, Stevens LK, Emery C, Fuller JH: EURODIAB Prospective Complications Study Group Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care 2009;32:1896–1900
    1. Gelber DA, Pfeifer MA, Broadstone VL, Munster EW, Peterson M, Arezzo JC, Shamoon H, Zeidler A, Clements R, Greene DA: Components of variance for vibratory and thermal threshold testing in normal and diabetic subjects. J Diabetes Complicat 1995;9:170–176
    1. Bril V, Kojic J, Ngo M, Clark K: Comparison of a neurothesiometer and vibration in measuring vibration perception thresholds and relationship to nerve conduction studies. Diabetes Care 1997;20:1360–1362
    1. Chong PS, Cros DP: Technology literature review: quantitative sensory testing. Muscle Nerve 2004;29:734–747
    1. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, Waberski BH, Lachin JM: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Diabetes Care 2010;33:1090–1096
    1. Albers JW, Herman WH, Pop-Busui R, Martin CL, Cleary P, Waberski B: Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Intervention and Complications (EDIC) Research Group Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion: possible predictors of incident neuropathy? Diabetes Care 2007;30:2613–2618
    1. Papanas N, Papatheodorou K, Papazoglou D, Monastiriotis C, Christakidis D, Maltezos E: A comparison of the new indicator test for sudomotor function (Neuropad) with the vibration perception threshold and the clinical examination in the diagnosis of peripheral neuropathy in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2008;116:135–138
    1. Davis EA, Jones TW, Walsh P, Byrne GC: The use of biothesiometry to detect neuropathy in children and adolescents with IDDM. Diabetes Care 1997;20:1448–1453
    1. Bril V, Perkins BA: Comparison of vibration perception thresholds obtained with the neurothesiometer and the CASE IV and relationship to nerve conduction studies. Diabet Med 2002;19:661–666
    1. Redmond JM, McKenna MJ, Feingold M, Ahmad BK: Sensory testing versus nerve conduction velocity in diabetic polyneuropathy. Muscle Nerve 1992;15:1334–1339

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться